Edition:
India

Insider Trading: TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

5.61USD
1:30am IST
Change (% chg)

$-0.07 (-1.23%)
Prev Close
$5.68
Open
$5.73
Day's High
$5.76
Day's Low
$5.58
Volume
268,873
Avg. Vol
526,226
52-wk High
$7.00
52-wk Low
$3.50

All Insider Trades
Trading Date Name Title Type Shares Traded Price
8 Dec 2017

Thompson (Tommy G)

Director Buy 5,000 $6.21
1 Dec 2017

Finizio (Robert G)

Chief Executive Officer Gift 250,000 $0.00
30 Nov 2017

Bernick (Brian A)

Director Gift 25,000 $0.00
29 Nov 2017

Milligan (John C K IV)

President Gift 20,000 $0.00
30 Aug 2017

Thompson (Tommy G)

Director Buy 5,000 $5.99
2 Mar 2017

Milligan (John C K IV)

President Gift 100,000 $0.00
30 Dec 2016

Finizio (Robert G)

Chief Executive Officer Gift 7,500 $0.00
29 Dec 2016

Finizio (Robert G)

Chief Executive Officer Gift 165,000 $0.00
27 Dec 2016

Bernick (Brian A)

Director Gift 30,000 $0.00
6 May 2016

Bernick (Brian A)

Director Buy 61,372 $0.41

Institutional Holders

% Shares Owned: 74.30%
# of Holders: 196
Total Shares Held: 160,805,458
3 Mo. Net Change: 582,301
# New Positions: 7
# Closed Positions: 4
# Increased Positions: 16
# Reduced Positions: 10
# Net Buyers: 6

Officers & Directors

Name Age Since Current Position

Tommy Thompson

76 2012 Independent Chairman of the Board

John Milligan

54 2011 President, Secretary, Director

Robert Finizio

46 2012 Chief Executive Officer, Director

Daniel Cartwright

59 2015 Chief Financial Officer, Treasurer

Mitchell Krassan

51 2011 Executive Vice President, Chief Strategy Officer

Michael Donegan

49 2013 Vice President - Finance

Brian Bernick

48 2013 Chief Clinical Officer, Director

Jules Musing

69 2013 Director

Jane Barlow

2018 Independent Director

J. Martin Carroll

68 2016 Independent Director

Cooper Collins

38 2012 Independent Director

Robert LaPenta

48 2012 Independent Director

Angus Russell

62 2015 Independent Director

Nicholas Segal

34 2012 Independent Director

David DeLucia

2015 Director, Investor Relations